Advancing the field of viroporins—Structure, function and pharmacology: IUPHAR Review X

Kira Devantier, Viktoria M.S. Kjær, Stephen Griffin, Birthe B. Kragelund, Mette M. Rosenkilde*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Abstract

Viroporins possess important potential as antiviral targets due to their critical roles during virus life cycles, spanning from virus entry to egress. Although the antiviral amantadine targets the M2 viroporin of influenza A virus, successful progression of other viroporin inhibitors into clinical use remains challenging. These challenges relate in varying proportions to a lack of reliable full-length 3D-structures, difficulties in functionally characterising individual viroporins, and absence of verifiable direct binding between inhibitor and viroporin. This review offers perspectives to help overcome these challenges. We provide a comprehensive overview of the viroporin family, including their structural and functional features, highlighting the moldability of their energy landscapes and actions. To advance the field, we suggest a list of best practices to aspire towards unambiguous viroporin identification and characterisation, along with considerations of potential pitfalls. Finally, we present current and future scenarios of, and prospects for, viroporin targeting drugs.
OriginalsprogEngelsk
TidsskriftBritish Journal of Pharmacology
Vol/bind181
Udgave nummer22
Sider (fra-til)4450-4490
ISSN0007-1188
DOI
StatusUdgivet - 2024

Bibliografisk note

Publisher Copyright:
© 2024 The Author(s). British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Citationsformater